Author: Sandra Henneking

Clearance Recognises Celldx-Tissue’s Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, Celldx-Tissue, has been cleared by the US Food and Drug… Continue reading Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA

We are proud that 15 of our abstracts have been accepted for the ASCO Annual Meeting 2026, including both online publications and on-site poster presentations. Our research projects address current challenges in modern oncology — ranging from molecular diagnostics and multi-omics analyses to innovative approaches for personalised therapies. We are especially looking forward to presenting… Continue reading Strong Presence at ASCO 2026: 15 Accepted Abstracts

This year, we will once again be present at the ESMO Congress. Following our successful participation in recent years, we are especially looking forward to Berlin. The congress will take place from 17–21 October 2025. Visit us at our booth and take the opportunity to exchange ideas with us on the latest developments in oncology.… Continue reading Join us at ESMO 2025 in Berlin

Following last year’s successful participation, we will once again be present with a booth at this year’s ESMO. This year’s congress will take place from September 13th – 17th in Barcelona. We look forward to welcoming you at our booth and discussing the latest developments in oncology with you! More information on our abstract submissions… Continue reading ESMO 2024 in Barcelona